While the advent of targeted therapies has significantly improved outcomes in patients with driver mutations such as EGFR, ALK, and KRAS, effective treatments for HER2 (ERBB2)-mutant NSCLC remain limited (9). This evidence concerns the gene ALK and non-small cell lung carcinoma.